Vol. 18/No. 23 | Oncology Live®

January 03, 2018

Plinabulin, an antineoplastic agent that activates an immune response, is being investigated as a treatment option for patients with advanced or metastatic non–small cell lung cancer who have progressed after standard-of-care therapy.

December 29, 2017

Rational combinations of immune checkpoint inhibitors with other standard antileukemic agents may be needed to improve the response rates, the durability of response, and the overall survival in patients with AML/MDS.

December 28, 2017

Biliary tract cancers are rare but deadly diseases, subdivided into intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, and gallbladder carcinoma.

December 27, 2017

In patients with common solid tumors, it is well-established that those with early-stage cancers have a statistically defined superior prognosis compared with those who present with and are required to be treated at later stages of the disease.

December 27, 2017

Daniel D. Von Hoff, MD, is focused on developing more targeted therapies for those with pancreatic and other advanced cancers.

December 27, 2017

After several decades without a new therapy, the approval of 4 treatments for acute myeloid leukemia over the span of just 4 months is either a total coincidence or an inevitable occurrence.

December 19, 2017

The introduction of cyclin-dependent kinase 4/6 inhibitors has resulted in a significant paradigm shift in the treatment of hormone receptor–positive breast cancer, helping to make the new agents part of rapidly developing improvements in personalized care for patients.

December 13, 2017

Mutations in the BRAF kinase are found in a relatively small number of patients with metastatic colorectal cancer, but they nonetheless have important implications for prognosis and response to standard therapy.

December 12, 2017

Tanios Bekaii-Saab, MD, FACP, and Rona D. Yaeger, MD, discuss the current treatment landscape and other key issues relating to this distinct subset of colorectal cancer.

December 12, 2017

Over the past few years, remarkable advances have been achieved in the field of chronic lymphocytic leukemia by rationally targeting pathways overexpressed and used by the malignant clone for proliferation and survival.